Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Pharmaceutical Lifecycle Management Strategies in 2017
Publication Date Apr 2017
Product Type Report
Single User License help $ 2995.00
Site User License help $ 5990.00
Corporate User License help $ 8985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.


Description

GBI Research’s latest report Pharmaceutical Lifecycle Management Strategies in 2017 provides a comprehensive assessment of product lifecycle (LCM) management strategies that are being implemented by pharmaceutical companies around the world. The pharmaceutical industry remains highly competitive and lucrative, and companies are investing significant time and resources into implementing strategies aimed at preserving the revenue streams of their products by extending patent life, delaying competition or slowing the pace of revenue loss following the end of market exclusivity.

The study, delivered in the form of an 82-slide PowerPoint presentation investigates a wide range of commercial, developmental, legal and regulatory strategies. This report format allows you to easily assemble high-quality presentations and research material to meet a variety of corporate requirements. Our research deep dives into the rationale for implementing LCM strategies, as well as the challenges, risks and commercial opportunities they represent. Moreover, detailed case studies showcasing recent real-world examples of LCM strategies will enable understanding of the key factors that determined their success. Information leveraged from our robust industry-leading database also highlights strategies being implemented for products currently in development.

The pharmaceutical industry will continue to face a wide range of challenges in the coming years, including patent cliffs, declining productivity, intensifying levels of competition from generic and biosimilar manufacturers, low reimbursement levels and stricter regulatory policies. Careful LCM planning will continue to be a crucial element of the industry’s ability to answer these problems.

GBI Research conducted extensive research to provide a comprehensive understanding of the LCM strategies being implemented by players in the pharmaceutical industry. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.
Scope

    What is driving the need for effective LCM strategies in the pharmaceutical industry?

    What are the most common LCM strategies being implemented?

    What are the business opportunities and commercial rewards arising from the implementation of LCM strategies?

    What are the key factors that impact the choice of LCM strategy?

    What strategies have Big Pharma companies implemented in recent years to preserve revenues and market share?

Reasons To Buy

    This report will allow you to:

    Gain insights into the rationale for implementing LCM strategies, alongside their key challenges, risks and potential benefits.

    Understand the key challenges that the pharmaceutical industry has been facing in recent years

    Assess real-world examples of successful strategies implemented in the past, and the key factors that determined their success.

    Obtain information on strategies for products currently in development.


Table of Contents

Introduction

2. Executive Summary

3. Introduction to Pharmaceutical Lifecycle Management Strategies

3.1 The Pharmaceutical Product Lifecycle Curve

3.2 Key Objectives of Life Cycle Management Strategies in the Pharmaceutical Industry

3.3 What is Driving the Need for Effective Lifecycle Management Strategies in the Pharmaceutical Industry?

3.4 Classification and Benefits of Different Lifecycle Management Strategies for Pharma

3.5 Business Opportunities Created by LCM Strategies

3.6 Factors Impacting Choice of Lifecycle Strategies

4. Pharmaceutical Lifecycle Management – Commercial Strategies

4.1 Rx-to-OTC Switch as an LCM Strategy

4.1.1 RX-to-OTC Switch Case Studies

4.2 Geographical Expansion

4.3 Contract Research Organizations Helping Overcome Industry Challenges

4.3.1 Benefits from Partnering with Contract Development and Manufacturing Organizations (CDMOs)

4.3.2 Strategic Partnerships with CROs: Case studies

4.4 Pricing and Reimbursement Strategies for LCM in Pharma

4.4.1 Key Factors and Strategies to Consider when Making Pricing Decisions

4.4.2 Common Pricing Strategies in Pharma

4.4.3 A Systematic Value Development Plan to Achieve Optimum Reimbursement

4.5 Customer Retention Programs as LCM Strategies for Pharma

4.5.1 Role of Medical Publications in LCM Optimization

4.6 Asset Transactions as an LCM Tactic

4.6.1 Strategic Divestitures by Type and Recent Examples

5. Regulatory and Legal Strategies

5.1 Data Exclusivity

5.2 Orphan Drug Exclusivity

5.3 Pediatric exclusivity

6. Developmental Strategies

6.1 Introduction and Classification of Developmental Strategies

6.2 Indication Expansion

6.2.1 Key Consideration When Planning for Indication Expansion

6.2.2 Indication Expansion Case Study

6.3 Reformulation

6.3.1 Next-Generation Products: Introduction and Key Strategic Considerations

6.3.2 Types of Next-Generation Products

6.3.2.1 Metabolites

6.3.2.2 Chiral Switching

6.3.2.3 Polymorphs

6.3.3 Next-Generation Products: Case Study

6.3.4 New Modes of Drug Delivery

6.3.4.1 Dosage Form: Case study

6.3.4.2 Route of Administration: Case Study

6.3.4.3 Drug delivery technologies: Case Study

6.4 Combination Drugs

6.4.1 Combination Drugs: Case Study

7. Successful LCM Strategies Employed by Big Pharma: Case Studies

7.1 Pfizer

7.2 AstraZeneca

7.3 Teva

7.4 AbbVie

7.5 Roche & GSK

7.6 Cipla

7.7 Unsuccessful Implementation of LCM Strategies: Case Study

8. Patent Expiry Dates of Bestselling Pharmaceuticals 2005–2016

9. Life Cycle Management Strategies of Pipeline Products 2017

9.1 Eisai

9.2 Merck & Co

9.3 Johnson & Johnson

9.4 Takeda

9.5 AbbVie

10. Bibliography

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
Global Dental Laboratory Handpieces Consumption 2016 Market Research Report
By QYResearch
The Global Dental Laboratory Handpieces Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratory Handpieces market. First, the report ...Read More
Jan 2016 $4000.00
Back to Report Store Home Cardiovascular Disorders Drug Development Pipeline Review, 2017
By GBI Research
Description Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Mar 2017 $3995.00
Back to Report Store Home Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes
By GBI Research
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation
By GBI Research
Description Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare a ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
By GBI Research
Description Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapi ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
By GBI Research
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential
By GBI Research
Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or a ...Read More
Jan 2017 $6995.00
Back to Report Store Home Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline
By GBI Research
GBI Research’s latest report: “Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline” is a comprehensive, granular analysis of the 25,522 ...Read More
May 2017 $2995.00
Back to Report Store Home Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
By GBI Research
Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced diseas ...Read More
Sep 2015 $4995.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  GBI Research

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z